- |||||||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Alvesco (Twitter) - Jun 2, 2021
- |||||||||| niclosamide nasal spray (UNI91103) / UNION Therap, Institut Pasteur Korea, Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
New P2/3 trial: PROTECT-V: PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V (clinicaltrials.gov) - May 2, 2021 P2/3, N=1500, Recruiting,
- |||||||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi, Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Clinical, Journal: Use of Assist Devices to Actuate Pressurized Metered-Dose Inhalers in Elderly Patients with Asthma. (Pubmed Central) - Feb 7, 2021 Recruiting --> Completed | Trial primary completion date: Sep 2020 --> Jan 2021 Finger muscle strength should be considered when selecting a device for older patients with asthma, and the use of a pMDI assist device to push the canister is recommended in patients with weaker finger muscles.
- |||||||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Trial completion date, Trial primary completion date: A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19 (clinicaltrials.gov) - Feb 4, 2021 P2, N=66, Recruiting, Finger muscle strength should be considered when selecting a device for older patients with asthma, and the use of a pMDI assist device to push the canister is recommended in patients with weaker finger muscles. Trial completion date: Dec 2020 --> Mar 2021 | Trial primary completion date: Dec 2020 --> Mar 2021
- |||||||||| Xolair (omalizumab) / Roche, Novartis, Onbrez (indacaterol) / Novartis
Journal: Drugs for asthma. (Pubmed Central) - Jan 26, 2021 Trial completion date: Dec 2020 --> Mar 2021 | Trial primary completion date: Dec 2020 --> Mar 2021 No abstract available
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Journal: Drugs for COPD. (Pubmed Central) - Dec 30, 2020 N=615 --> 820 No abstract available
- |||||||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Clinical, Journal: Evaluation of Valved Holding Chambers Simulating Repurposing Use of Ciclesonide Metered-dose Inhaler by Patients with Pneumonia (Pubmed Central) - Dec 16, 2020 The purpose of this study was to evaluate the effect of five valved holding chambers (VHCs) on the inhalation of ciclesonide from Alvesco MDI...However, the use of VHC reduced the FPD of the formulation by increasing the time between the MDI discharge and the pump suction by various degrees among the five VHCs. These results indicated that use of the VHCs and minimizing the inhalation delay time should ensure sufficient inhalation of ciclesonide particles.
- |||||||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Phase classification, Enrollment change, Trial completion date, Trial primary completion date: COVERAGE: Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation (clinicaltrials.gov) - Nov 30, 2020 P2/3, N=615, Recruiting, These results indicated that use of the VHCs and minimizing the inhalation delay time should ensure sufficient inhalation of ciclesonide particles. Phase classification: P3 --> P2/3 | N=338 --> 615 | Trial completion date: Jan 2021 --> Aug 2021 | Trial primary completion date: Dec 2020 --> Aug 2021
- |||||||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Enrollment open: Inhaled Ciclesonide for Outpatients With COVID19 (clinicaltrials.gov) - Oct 19, 2020 P2/3, N=454, Recruiting, If the hypotheses that pneumonia exacerbation rate reduction is more significant in the ciclesonide treatment group than in the symptomatic treatment group and that ciclesonide is safe for use are valid, ciclesonide (Alvesco R) will serve as an important therapeutic option for COVID-19 patients. Not yet recruiting --> Recruiting
- |||||||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19 (clinicaltrials.gov) - Sep 15, 2020 P2, N=94, Recruiting, N=634 --> 338 Not yet recruiting --> Recruiting | N=141 --> 94 | Trial completion date: Sep 2020 --> Dec 2020 | Trial primary completion date: Jun 2020 --> Dec 2020
- |||||||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Enrollment open, Trial completion date, Trial primary completion date: COVERAGE: Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation (clinicaltrials.gov) - Jun 11, 2020 P3, N=1057, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Aug 2020 --> Jan 2021 | Trial primary completion date: Jul 2020 --> Dec 2020
- |||||||||| Alvesco (ciclesonide) / Takeda
Journal: 1064 nm Dispersive Raman Micro-Spectroscopy and Optical Trapping of Pharmaceutical Aerosols. (Pubmed Central) - Mar 29, 2019 ...We analyze microparticles (1-5 μm diameter) composed of polystyrene latex and from three real-world pressurized metered dose inhalers (pMDIs) used in the treatment of asthma: salmeterol xinafoate (Serevent), salbutamol sulfate (Salamol), and ciclesonide (Alvesco)...Spectra of individual pMDI particles compare well to bulk samples and the Serevent pMDI delivers the thermodynamically preferred crystal form of salmeterol xinafoate. 1064 nm dispersive Raman micro-spectroscopy is a promising technique which could see diverse applications for samples where fluorescence-free characterisation is required with high spatial resolution.
- |||||||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Trial completion date, Trial initiation date, Trial primary completion date: Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma (clinicaltrials.gov) - Feb 25, 2019 P=N/A, N=110, Not yet recruiting, 1064 nm dispersive Raman micro-spectroscopy is a promising technique which could see diverse applications for samples where fluorescence-free characterisation is required with high spatial resolution. Trial completion date: Dec 2020 --> Dec 2021 | Initiation date: Jan 2019 --> Sep 2019 | Trial primary completion date: Jun 2020 --> Jun 2021
- |||||||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Trial completion date, Trial initiation date, Trial primary completion date: Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma (clinicaltrials.gov) - Aug 21, 2018 P=N/A, N=110, Not yet recruiting, Trial completion date: Dec 2020 --> Dec 2021 | Initiation date: Jan 2019 --> Sep 2019 | Trial primary completion date: Jun 2020 --> Jun 2021 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Jun 2020 | Initiation date: Jun 2018 --> Jan 2019
- |||||||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Trial completion date, Trial initiation date, Trial primary completion date: Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma (clinicaltrials.gov) - Mar 5, 2018 P=N/A, N=110, Not yet recruiting, Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Jun 2020 | Initiation date: Jun 2018 --> Jan 2019 Trial completion date: Sep 2019 --> Dec 2019 | Initiation date: Sep 2017 --> Jun 2018 | Trial primary completion date: Sep 2019 --> Dec 2019
- |||||||||| Omnaris (ciclesonide nasal spray) / Covis Pharma, Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Trial completion, Enrollment change, Trial primary completion date: Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis (clinicaltrials.gov) - Jul 23, 2016 P4, N=25, Completed, Trial completion date: Sep 2019 --> Dec 2019 | Initiation date: Sep 2017 --> Jun 2018 | Trial primary completion date: Sep 2019 --> Dec 2019 Recruiting --> Completed | N=60 --> 25 | Trial primary completion date: Dec 2014 --> Aug 2015
- |||||||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Enrollment change, Trial termination, Trial primary completion date: Asthma/Steroid Withdrawal Study (clinicaltrials.gov) - May 26, 2016 P4, N=6, Terminated, Recruiting --> Completed | N=60 --> 25 | Trial primary completion date: Dec 2014 --> Aug 2015 N=20 --> 6 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2010 --> Oct 2015; This project will resume upon the completion of other research committments.
- |||||||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Trial completion, Trial primary completion date: Effect of High Dose Ciclesonide on Asthma Control (clinicaltrials.gov) - Apr 7, 2015 P3, N=450, Completed, Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Oct 2013 --> Aug 2014
|